A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Myocardial infarction; Stroke; Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PREVENT-HD
- Sponsors Janssen Research & Development
- 23 Nov 2023 Results of meta-analysis from NCT04504032 and NCT04508023 study analyzing antithrombotic prophylaxis with rivaroxaban in patients with prehospital COVID-19, published in the Thrombosis and Haemostasis
- 08 May 2023 Status changed to discontinued.
- 08 May 2023 Results assessing effect of Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19published in the Circulation